Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

Compares two treatment combinations for a fast-growing blood cancer called DLBCL

Tests zilovertamab vedotin with standard chemotherapy in adults with newly diagnosed lymphoma.

Plain-language title generated from the registry record
Registry title: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Key facts

Where
Amarillo, Aurora, Austin, Baton Rouge, Boca Raton, Boston, Bozeman, Buffalo, Burbank, Burnsville, Chandler, Chapel Hill, Charleston, Charlotte, Chicago, Cincinnati, Cleveland, Dallas, Duarte, Edgewood, Elizabethtown, Glendale, Goodyear, Grand Junction, Hot Springs, Iowa City, Jacksonville, Knoxville, La Jolla, Lexington, Lincoln, Louisville, Madison, Manassas, Mayfield Heights, Miami Beach, Milwaukee, Mineola, Mobile, Monroe, Morristown, Murray, Nashville, New Orleans, New York, Newark, Omaha, Orange City, Palestine, Paramus, Peoria, Philadelphia, Portland, Post Falls, Richmond, San Antonio, Sellersville, Shreveport, St. George, Syracuse, Tyler, Vancouver, Walnut Creek, Washington D.C., Waukee, Westbury, Winston-Salem, and York, United StatesSee the 74 sites
Phase
Phase 2

Where in United States

  • Texas Oncology - West Texas (Site 8008)Amarillo, United StatesTaking people
  • Rocky Mountain Cancer Centers (RMCC) (Site 8001)Aurora, United StatesTaking people
  • Texas Oncology - Central/South Texas (Site 8006)Austin, United StatesTaking people
  • Our Lady of the Lake Physician Group-Medical Oncology (Site 0180)Baton Rouge, United StatesTaking people
  • Boca Raton Regional Hospital-Lynn Cancer Institute (Site 0130)Boca Raton, United StatesTaking people
  • Beth Israel Deaconess Medical Center (Site 0161)Boston, United StatesTaking people
  • Dana Farber Cancer Institute (Site 0111)Boston, United StatesTaking people
  • Bozeman Health Deaconess Hospital (Site 0183)Bozeman, United StatesTaking people
  • Roswell Park Cancer Institute (Site 0192)Buffalo, United StatesTaking people
  • Erie County Medical Center (Site 0175)Buffalo, United StatesNo longer taking part
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center (Site 0135)Burbank, United StatesTaking people
  • Minnesota Oncology Hematology (MNO) (Site 8004)Burnsville, United StatesTaking people
  • Ironwood Cancer & Research Centers (Site 0204)Chandler, United StatesTaking people
  • University of North Carolina Medical Center (Site 0136)Chapel Hill, United StatesTaking people
  • Medical University of South Carolina (Site 0153)Charleston, United StatesTaking people
  • Novant Health Presbyterian Medical Center (Site 0177)Charlotte, United StatesTaking people
  • University of Chicago Medical Center (Site 0126)Chicago, United StatesTaking people
  • University of Cincinnati Medical Center (Site 0156)Cincinnati, United StatesTaking people
  • Cleveland Clinic Main (Site 0101)Cleveland, United StatesTaking people
  • Fairview Hospital-Moll Cancer Center (Site 0198)Cleveland, United StatesTaking people
  • University Hospitals of Cleveland (Site 0155)Cleveland, United StatesTaking people
  • UT Southwestern Medical Center (Site 0190)Dallas, United StatesTaking people
  • City of Hope Comprehensive Cancer Center (Site 0191)Duarte, United StatesTaking people
  • Saint Elizabeth Medical Center Edgewood (Site 0141)Edgewood, United StatesTaking people
  • Baptist Health Hardin (Site 0154)Elizabethtown, United StatesTaking people
  • Palo Verde Cancer Specialists (Site 0105)Glendale, United StatesTaking people
  • City of Hope - Phoenix (Site 0202)Goodyear, United StatesTaking people
  • Colorado West Healthcare System-Grand Valley Oncology (Site 0165)Grand Junction, United StatesTaking people
  • Genesis Cancer and Blood Institute (Site 0193)Hot Springs, United StatesTaking people
  • University of Iowa-Holden Comprehensive Cancer Center (Site 0139)Iowa City, United StatesTaking people
  • Baptist MD Anderson Cancer Center (Site 0176)Jacksonville, United StatesTaking people
  • Tennessee Cancer Specialists (Site 7004)Knoxville, United StatesTaking people
  • Moores Cancer Center (Site 0187)La Jolla, United StatesTaking people
  • Baptist Health Lexington (Site 0127)Lexington, United StatesTaking people
  • NHO Revive Research Institute, LLC (Site 0121)Lincoln, United StatesTaking people
  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews (Site 0185)Louisville, United StatesTaking people
  • SSM Health Dean Medical Group (Site 0106)Madison, United StatesTaking people
  • Virginia Cancer Specialists, PC (Site 8003)Manassas, United StatesTaking people
  • Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center (Site 0199)Mayfield Heights, United StatesTaking people
  • Mount Sinai Braman Comprehensive Cancer Center (Site 0140)Miami Beach, United StatesTaking people
  • Medical College of Wisconsin (Site 0103)Milwaukee, United StatesTaking people
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island (Site 0208)Mineola, United StatesTaking people
  • Infirmary Cancer Care (Site 0157)Mobile, United StatesTaking people
  • Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic (Site 0209)Monroe, United StatesTaking people
  • Atlantic Health Morristown Medical Center (Site 0163)Morristown, United StatesTaking people
  • Intermountain Medical Center (Site 0182)Murray, United StatesTaking people
  • SCRI Oncology Partners (Site 7002)Nashville, United StatesTaking people
  • Ochsner Clinic Foundation (Site 0189)New Orleans, United StatesTaking people
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 0108)New York, United StatesTaking people
  • Medical Oncology Hematology Consultants (MOHC) (Site 8007)Newark, United StatesTaking people
  • University Of Nebraska Medical Center (Site 0110)Omaha, United StatesTaking people
  • Mid Florida Hematology and Oncology Center (Site 0152)Orange City, United StatesTaking people
  • Texas Oncology - Northeast Texas (Site 8002)Palestine, United StatesTaking people
  • Valley Health Systems - Ridgewood Campus (Site 0125)Paramus, United StatesTaking people
  • Illinois Cancer Care (Site 7005)Peoria, United StatesTaking people
  • Abramson Cancer Center and Perelman Center for Advanced Medicine (Site 0131)Philadelphia, United StatesTaking people
  • Temple University Hospital (Site 0133)Philadelphia, United StatesTaking people
  • Providence Oncology and Hematology Clinic Westside (Site 0179)Portland, United StatesTaking people
  • Providence Portland Medical Center (Site 0120)Portland, United StatesTaking people
  • Beacon Cancer Care (Site 0142)Post Falls, United StatesTaking people
  • VCU Health Adult Outpatient Pavillion (Site 0138)Richmond, United StatesTaking people
  • Texas Oncology - San Antonio (Site 8009)San Antonio, United StatesTaking people
  • Alliance Cancer Specialists (ACS) (Site 8010)Sellersville, United StatesTaking people
  • Louisiana State University Health Sciences Shreveport (Site 0195)Shreveport, United StatesTaking people
  • Intermountain Healthcare - St. George (Site 0203)St. George, United StatesTaking people
  • SUNY Upstate Cancer Center (Site 0178)Syracuse, United StatesTaking people
  • The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center (Site 0145)Tyler, United StatesNo longer taking part
  • Northwest Cancer Specialists (Compass Oncology) (Site 8000)Vancouver, United StatesTaking people
  • Bass Medical Group (Site 0123)Walnut Creek, United StatesTaking people
  • Georgetown University Medical Center (Site 0117)Washington D.C., United StatesTaking people
  • Mission Blood & Cancer Care (Site 0114)Waukee, United StatesTaking people
  • Optum Medical Care, PC (Site 0122)Westbury, United StatesTaking people
  • Novant Health Forsyth Medical Center (Site 0206)Winston-Salem, United StatesTaking people
  • Cancer Care Associates Of York (Site 0174)York, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Merck Sharp & Dohme LLC
Trial code
NCT06890884EU 2024-515526-89-00
Record updated
3 November 2026
Original description
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.Read full original descriptionShow less

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.

The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Inclusion: The main inclusion criteria include but are not limited to the following:; Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues; Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale; Has received no prior treatment for their DLBCL; Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART); Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization; Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

Exclusion: Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma; Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication; Has ongoing corticosteroid therapy; Has a history of transformation of indolent disease to DLBCL; Has a demyelinating form of Charcot-Marie-Tooth disease; HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Known additional malignancy that is progressing or has required active treatment within the past 2 years; Has active autoimmune disease that has required systemic treatment in the past 2 years; Has active infection requiring systemic therapy; Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection; Has history of stem cell/solid organ transplant; The main exclusion criteria include but are not limited to the following:; Has Ann Arbor Stage I DLBCL; Has clinically significant pericardial or pleural effusion; Has ongoing Grade >1 peripheral neuropathy; Known active central nervous system (CNS) lymphoma.

ClinicalTrials.gov NCT06890884 · EU CTIS 2024-515526-89-00